Janus Henderson Group
CORT icon

Janus Henderson Group’s Corcept Therapeutics CORT Stock Holding History

Janus Henderson Group’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$6.61M Buy
164,074
+10,817
+7% +$404K ﹤0.01% 878
2025
Q4 		$5.33M Buy
153,257
+111,598
+268% +$8.77M ﹤0.01% 915
2025
Q3 		$3.46M Sell
41,659
-63,061
-60% -$4.56M ﹤0.01% 1072
2025
Q2 		$7.69M Sell
104,720
-142,119
-58% -$10.3M ﹤0.01% 779
2025
Q1 		$13.5M Sell
246,839
-54,651
-18% -$3.33M 0.01% 644
2024
Q4 		$15.2M Sell
301,490
-22,527
-7% -$1.18M 0.01% 645
2024
Q3 		$15M Sell
324,017
-17,793
-5% -$632K 0.01% 622
2024
Q2 		$11.1M Buy
341,810
+76,761
+29% +$2.1M 0.01% 660
2024
Q1 		$6.68M Buy
265,049
+219,551
+483% +$5.19M ﹤0.01% 783
2023
Q4 		$1.48M Sell
45,498
-69
-0.2% -$1.9K ﹤0.01% 1413
2023
Q3 		$1.24M Buy
45,567
+21
+0% +$608 ﹤0.01% 1444
2023
Q2 		$1.01M Sell
45,546
-80,254
-64% -$1.85M ﹤0.01% 1611
2023
Q1 		$2.72M Sell
125,800
-17,015
-12% -$373K ﹤0.01% 1106
2022
Q4 		$2.9M Sell
142,815
-284,348
-67% -$7.13M ﹤0.01% 998
2022
Q3 		$11M Buy
427,163
+274,652
+180% +$7.35M 0.01% 654
2022
Q2 		$3.63M Buy
152,511
+23,247
+18% +$506K ﹤0.01% 907
2022
Q1 		$2.91M Sell
129,264
-47,327
-27% -$1.01M ﹤0.01% 1131
2021
Q4 		$3.5M Buy
176,591
+15,249
+9% +$309K ﹤0.01% 1157
2021
Q3 		$3.17M Sell
161,342
-30,276
-16% -$634K ﹤0.01% 1154
2021
Q2 		$4.22M Sell
191,618
-28,740
-13% -$640K ﹤0.01% 1097
2021
Q1 		$5.24M Buy
220,358
+79,693
+57% +$2.13M ﹤0.01% 1001
2020
Q4 		$3.68M Buy
140,665
+20,928
+17% +$441K ﹤0.01% 1024
2020
Q3 		$2.08M Buy
119,737
+21,642
+22% +$345K ﹤0.01% 1051
2020
Q2 		$1.65M Buy
98,095
+78,205
+393% +$1.1M ﹤0.01% 1056
2020
Q1 		$236K Sell
19,890
-46,434
-70% -$575K ﹤0.01% 1247
2019
Q4 		$803K Buy
66,324
+3,758
+6% +$52.3K ﹤0.01% 1244
2019
Q3 		$884K Buy
62,566
+7,874
+14% +$96.8K ﹤0.01% 1231
2019
Q2 		$610K Sell
54,692
-1,325
-2% -$14.8K ﹤0.01% 1247
2019
Q1 		$658K Buy
+56,017
New +$696K ﹤0.01% 1212

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

Janus Henderson Group's CORT Position: Q1 2026 in Review

Janus Henderson Group increased its Corcept Therapeutics (CORT) stake by 7.1% in Q1 2026, buying an estimated $404K and bringing the position to 164,074 shares worth $6.61M. The position accounts for ﹤0.01% of the portfolio, ranked #878.

Janus Henderson Group first reported a position in CORT in Q1 2019 and has held it in 29 quarters since. The position peaked at $15.2M in Q4 2024. 352 funds tracked by Wall St. Rank hold CORT as of Q1 2026.

  • Janus Henderson Group held 164,074 shares of Corcept Therapeutics worth $6.61M as of Q1 2026.
  • Janus Henderson Group bought 10,817 Corcept Therapeutics shares in Q1 2026, an estimated $404K.
  • Corcept Therapeutics made up ﹤0.01% of Janus Henderson Group's portfolio in Q1 2026, its #878 holding.
  • Janus Henderson Group first reported a position in Corcept Therapeutics in Q1 2019 and has held it in 29 quarters since.
  • Janus Henderson Group's Corcept Therapeutics position peaked at $15.2M in Q4 2024.
  • 352 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q1 2026.

Based on Janus Henderson Group's 13F filing for Q1 2026, filed 15 May 2026.